21.47 0.00 (0.00%)
After hours: 4:07PM EDT
|Bid||21.45 x 1000|
|Ask||21.46 x 2200|
|Day's Range||21.40 - 22.18|
|52 Week Range||21.29 - 46.98|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.23|
Taking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Alkermes plc...
Alkermes Plc NASDAQ/NGS:ALKSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ALKS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALKS. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALKS are favorable, with net inflows of $4.00 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune ...
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011. This analysis aims first to contrast CEO...
-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia -- DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ...
DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global ...
-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ...